Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients:A retrospective study of 525 patients

被引：4

作者：

Yu-tuan Wu ^{[1
]}

Xin Li ^{[1
]}

Lin-jie Lu ^{[2
]}

Lu Gan ^{[3
]}

Wei Dai ^{[1
]}

Yan-ling Shi ^{[1
]}

Vishnu Prasad Adhikari ^{[1
]}

Kai-nan Wu ^{[1
]}

Ling-quan Kong ^{[1
]}

机构：

[1] Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University

[2] Department of Thyroid and Breast Surgery, Liuzhou People's Hospital

[3] Department of Oncology and Radiology, the First Affiliated Hospital of Chongqing Medical University

来源：

TheJournalofBiomedicalResearch | 2018年 / 32卷 / 03期

基金：

中国国家自然科学基金;

关键词：

breast cancer; neoadjuvant chemotherapy; hormone receptors; Ki67;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 ;

摘要：

This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor(ER), progesterone receptor(PR) and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry.Differences between specimens made through preoperative core needle biopsy and excised tissue biopsy were observed. The positive rates of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy were 65.3% and 63.2%, 51.0% and 42.6%, 65.6% and 43.4%, respectively. The expression of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy had no statistically significant difference. However, after neoadjuvant chemotherapy, the discordance rates of ER, PR and Ki67 were 15.2%(79/521), 26.9%(140/520) and 44.8%(225/502), respectively. The ER, PR and Ki67 status changed from positive to negative in 7.5%(39/521), 13.3%(69/520) and 21.1%(106/502) of the patients, whereas ER, PR and Ki67 status changed from negative to positive in 7.7%(40/521), 13.6%(71/520)and 23.7%(119/502) of the patients, respectively. These results showed that the status of some biomarkers changes after neoadjuvant chemotherapy and biomarker status needs to be reexamined to optimize adjuvant systemic therapy and better prognosis assessment.

引用

页码：191 / 197

页数：7

共 23 条

[1]

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial[J] . Cornelis JH van de Velde,Daniel Rea,Caroline Seynaeve,Hein Putter,Annette Hasenburg,Jean-Michel Vannetzel,Robert Paridaens,Christos Markopoulos,Yasuo Hozumi,Elysee TM Hille,Dirk G Kieback,Lina Asmar,Jan Smeets,Johan WR Nortier,Peyman Hadji,John MS Bartlett,Stephen E Jones. &nbspThe Lancet . 2011 (9762)

[2]

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials[J] . Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). &nbspThe Lancet . 2011 (9793)

[3] Alternation of Estrogen Receptor and Progesterone Receptor Expression in Primary Breast Cancer Patients Treated with Neoadjuvant Chemotherapy [J].

Kitagawa, Dai ;

Saji, Shigehira ;

Horiguchi, Shin-ichiro ;

Satoh, Yu ;

Horiguchi, Kazumi ;

Toi, Masakazu ;

Funata, Nobuaki ;

Kuroi, Katsumasa .

BREAST JOURNAL, 2010, 16 (04) :435-436

[4]

Neo-endocrinochemotherapy: A novel approach for enhancing chemotherapeutic efficacy in clinic?[J] . Jianbo Huang,Guangyan Ji,Lei Xing,Hongyuan Li,Ziwei Wang,Guosheng Ren,Kainan Wu,Lingquan Kong. &nbspMedical Hypotheses . 2013

[5] Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer [J].

von Minckwitz, Gunter ;

Schmitt, Wolfgang D. ;

Loibl, Sibylle ;

Mueller, Berit M. ;

Blohmer, Jens U. ;

Sinn, Bruno V. ;

Eidtmann, Holger ;

Eiermann, Wolfgang ;

Gerber, Bernd ;

Tesch, Hans ;

Hilfrich, Joern ;

Huober, Jens ;

Fehm, Tanja ;

Barinoff, Jana ;

Ruediger, Thomas ;

Erbstoesser, Erhard ;

Fasching, Peter A. ;

Karn, Thomas ;

Mueller, Volkmar ;

Jackisch, Christian ;

Denkert, Carsten .

CLINICAL CANCER RESEARCH, 2013, 19 (16) :4521-4531

[6]

Global cancer statistics, 2012[J] . Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet‐Tieulent,Ahmedin Jemal. &nbspCA: A Cancer Journal for Clinicians . 2015 (2)

[7]

Prognostic significance of pathologic complete response and Ki67expression after neoadjuvant chemotherapy in breast cancer. Yoshioka T,Hosoda M,Yamamoto M,et al. Breast Cancer . 2015

[8]

Strategies for subtypesdealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. W. C. Wood,A. S. Coates,R. D. Gelber,B. Thrlimann,H.-J. Senn. Annals of Oncology . 2011

[9]

Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy[J] . Masako Kasami,Takayoshi Uematsu,Masatake Honda,Tsugumi Yabuzaki,Junichi Sanuki,Yoshihiro Uchida,Haruhiko Sugimura. &nbspThe Breast . 2008 (5)

[10]

The Effect of Neoadjuvant Chemotherapy on Histologic Grade, Hormone Receptor Status, and Her2/neu Status in Breast Carcinoma[J] . Amy L.Adams,IsamEltoum,HelenKrontiras,WenquanWang,David C.Chhieng. &nbspThe Breast Journal . 2008 (2)

← 1 2 3 →